AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. (Q45876170)

17 December 2017

title

AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. (English)

1 reference

17 December 2017

0 references

1 reference

glycogen storage disease

1 reference

15

Yuan-Tsong Chen

1 reference

17 December 2017

author name string

Dwight D Koeberl

1

1 reference

17 December 2017

Carlos Pinto

2

1 reference

17 December 2017

Baodong Sun

3

1 reference

17 December 2017

Songtao Li

4

1 reference

17 December 2017

Daniel M Kozink

5

1 reference

17 December 2017

Daniel K Benjamin

6

1 reference

17 December 2017

Amanda K Demaster

7

1 reference

17 December 2017

Meghan A Kruse

8

1 reference

17 December 2017

Valerie Vaughn

9

1 reference

17 December 2017

Steven Hillman

10

1 reference

17 December 2017

Andrew Bird

11

1 reference

17 December 2017

Mark Jackson

12

1 reference

17 December 2017

Talmage Brown

13

1 reference

17 December 2017

Priya S Kishnani

14

1 reference

17 December 2017

publication date

11 March 2008

1 reference

17 December 2017

published in

Molecular Therapy

1 reference

17 December 2017

volume

16

1 reference

17 December 2017

issue

4

1 reference

17 December 2017

page(s)

665-672

1 reference

17 December 2017

Hepatocellular carcinoma in glycogen storage disease type Ia: a case series

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Correction of glycogen storage disease type 1a in a mouse model by gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Successful treatment of severe Type I glycogen storage disease with neonatal presentation by nocturnal intragastric feeding

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia).

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

The role of HNF1alpha, HNF3gamma, and cyclic AMP in glucose-6-phosphatase gene activation

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

The three insulin response sequences in the glucose-6-phosphatase catalytic subunit gene promoter are functionally distinct

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Sustained hepatic and renal glucose-6-phosphatase expression corrects glycogen storage disease type Ia in mice

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Decreased urinary citrate excretion in type 1a glycogen storage disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Glycogen storage disease type Ia in two littermate Maltese puppies.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Metabolic control and renal dysfunction in type I glycogen storage disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Cornstarch therapy in type I glycogen-storage disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Type I glycogen storage disease: nine years of management with cornstarch

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

The regulation of growth in glycogen storage disease type 1.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Liver transplantation for glycogen storage disease types I, III, and IV

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Long-term outcome of liver transplantation in patients with glycogen storage disease type Ia.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Hepatocellular carcinoma in children and effect of living-donor liver transplantation on outcome.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Outcome of living donor liver transplantation for glycogen storage disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

AAV vector integration sites in mouse hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

No evidence for tumorigenesis of AAV vectors in a large-scale study in mice.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Integration of adeno-associated virus (AAV) and recombinant AAV vectors

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Lack of Fas antagonism by Met in human fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Met provides essential signals for liver regeneration

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Invasive growth: from development to metastasis

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Transmembrane topology of glucose-6-phosphatase

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Quantitative histochemical analysis of glucose-6-phosphatase activity in rat liver using an optimized cerium-diaminobenzidine method

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.15

7 January 2021

Identifiers

DOI

10.1038/MT.2008.15

1 reference

17 December 2017

1 reference

17 December 2017